FISCHER vs GUJTHEM: Stock Comparison

Fischer Medical Ventures Limited vs Gujarat Themis Biosyn Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Gujarat Themis Biosyn Limited is the larger company by market capitalisation. Fischer Medical Ventures Limited shows a lower P/E, faster revenue growth and lower leverage, while Gujarat Themis Biosyn Limited shows a higher ROE, a higher dividend yield and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Fischer Medical Ventures Limited and Gujarat Themis Biosyn Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, FISCHER is more favourable on 6 of 13 scored metrics and GUJTHEM on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GUJTHEM is the larger company
₹3,926 Cr vs ₹2,486 Cr
P/E Ratio
FISCHER has a lower P/E
80.98x vs 84.23x
P/B Ratio
FISCHER has a lower P/B
6.48x vs 13.65x
EPS
GUJTHEM has higher earnings per share
₹4.27 vs ₹0.45
Dividend Yield
GUJTHEM has a higher dividend yield
0.18% vs 0.01%
Revenue Growth (TTM YoY)
FISCHER has faster revenue growth
98.7% vs 17.2%
EPS Growth (TTM YoY)
FISCHER has faster EPS growth
0% vs -9.1%
Qtr Sales Growth
FISCHER has stronger quarterly sales growth
98.8% vs 17.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricFISCHERGUJTHEM
SectorHealthcareHealthcare
IndustryMedical Equipment & SuppliesPharmaceuticals

Price

MetricFISCHERGUJTHEM
Live Price₹37.94₹360.5
Day Change-2.79%1.18%
Volume21.83 L32,351
52-Week High₹1,194.4₹479
52-Week Low₹31.05₹225.05
Distance from 52W High-96.82%-24.74%

Valuation

MetricFISCHERGUJTHEM
Market Cap₹2,486 Cr₹3,926 Cr
P/E Ratio80.98x84.23x
P/B Ratio6.48x13.65x
EPS₹0.45₹4.27
Book Value₹5.96₹26.41
Dividend Yield0.01%0.18%

Growth

MetricFISCHERGUJTHEM
Revenue Growth (TTM YoY)98.7%17.2%
EPS Growth (TTM YoY)0%-9.1%
Qtr Sales Growth98.8%17.2%
Qtr Profit Growth-642%-9.25%

Profitability & Leverage

MetricFISCHERGUJTHEM
ROE8.59%17.4%
ROCE11.4%17.9%
Net Margin6.79%28.15%
Operating Margin14%45.6%
Debt to Equity0.28x0.56x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricFISCHERGUJTHEM
Promoter Holding11.46% 0.82 pp70.86%
FII Holding4.97% 0.12 pp1.8% 0.16 pp
DII Holding1.38% 0.02 pp1.18% 0.01 pp
Public Holding31.5% 0.49 pp26.16% 0.16 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Fischer Medical Ventures Limited and Gujarat Themis Biosyn Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.